Comparing PepGen (NASDAQ:PEPG) and Affimed (NASDAQ:AFMD)

PepGen (NASDAQ:PEPGGet Free Report) and Affimed (NASDAQ:AFMDGet Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Institutional and Insider Ownership

71.8% of PepGen shares are held by institutional investors. Comparatively, 30.8% of Affimed shares are held by institutional investors. 4.0% of PepGen shares are held by insiders. Comparatively, 3.8% of Affimed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


This table compares PepGen and Affimed’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PepGen N/A -40.53% -34.31%
Affimed -357.49% -79.96% -60.31%

Risk and Volatility

PepGen has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Affimed has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for PepGen and Affimed, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PepGen 0 0 3 0 3.00
Affimed 0 1 7 0 2.88

PepGen currently has a consensus price target of $27.25, indicating a potential upside of 420.04%. Affimed has a consensus price target of $5.50, indicating a potential upside of 1,407.68%. Given Affimed’s higher probable upside, analysts plainly believe Affimed is more favorable than PepGen.

Valuation & Earnings

This table compares PepGen and Affimed’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PepGen N/A N/A -$69.10 million ($3.26) -1.61
Affimed $43.58 million 1.25 -$90.61 million ($0.78) -0.47

PepGen has higher earnings, but lower revenue than Affimed. PepGen is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.


PepGen beats Affimed on 7 of the 13 factors compared between the two stocks.

About PepGen

(Get Free Report)

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston, Massachusetts.

About Affimed

(Get Free Report)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with's FREE daily email newsletter.